IL2 and anemia: The incidence of decreased appetite (IL-2 + IFNα vs. sunitinib: 33% vs. 20%, p = 0.392), anemia (22% vs. 13%, p = 0.510), proteinuria (11% vs. 13%, p = 0.846), decreased neutrophil count (39% vs. 40%, p = 0.948), and decreased white blood cell count (44% vs. 40%, p = 0.797) was similar in both groups.